These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24685746)

  • 21. [CROI 2012: updates on raltegravir].
    MMW Fortschr Med; 2012 May; 154 Suppl 1():41. PubMed ID: 22916600
    [No Abstract]   [Full Text] [Related]  

  • 22. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.
    Ménard A; Solas C; Mokthari S; Bregigeon S; Drogoul MP; Tamalet C; Lacarelle B; Martin IP
    AIDS; 2009 Apr; 23(7):869-71. PubMed ID: 19363331
    [No Abstract]   [Full Text] [Related]  

  • 23. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raltegravir: is a 400 mg once-daily dose enough?
    Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
    J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
    Zhu L; Butterton J; Persson A; Stonier M; Comisar W; Panebianco D; Breidinger S; Zhang J; Bertz R
    Antivir Ther; 2010; 15(8):1107-14. PubMed ID: 21149917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection.
    Nanishi E; Hoshina T; Ohga S; Nishio H; Hara T
    J Microbiol Immunol Infect; 2015 Feb; 48(1):109-12. PubMed ID: 25074626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?
    Gervasoni C; Riva A; Impagnatiello C; Galli M; Cattaneo D
    Clin Infect Dis; 2013 Aug; 57(3):480-1. PubMed ID: 23616494
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis.
    Mena A; Vázquez P; Castro Á; López S; Bello L; Pedreira JD
    J Antimicrob Chemother; 2011 Apr; 66(4):951-2. PubMed ID: 21393209
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.
    Thomas M; Hopkins C; Duffy E; Lee D; Loulergue P; Ripamonti D; Ostrov DA; Phillips E
    Clin Infect Dis; 2017 May; 64(9):1198-1203. PubMed ID: 28369189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
    Nozza S; Galli L; Bigoloni A; Gianotti N; Spagnuolo V; Carbone A; Chiappetta S; Ripa M; Tambussi G; Lazzarin A; Castagna A
    New Microbiol; 2014 Apr; 37(2):145-51. PubMed ID: 24858641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosing of raltegravir when given with rifampicin.
    Meintjes G; Maartens G
    Lancet Infect Dis; 2014 Jun; 14(6):442-3. PubMed ID: 24726094
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raltegravir and rifampicin in patients with HIV and tuberculosis.
    Bierman WFW; Riezebos-Brilman A
    Lancet Infect Dis; 2014 Nov; 14(11):1047. PubMed ID: 25444406
    [No Abstract]   [Full Text] [Related]  

  • 38. Raltegravir and rifampicin in patients with HIV and tuberculosis.
    Klis S; Daskapan A; Akkerman OW; Alffenaar JW; Stienstra Y
    Lancet Infect Dis; 2014 Nov; 14(11):1046-1047. PubMed ID: 25444405
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 40. DRESS syndrome associated with raltegravir.
    Zhang KS; Modi GM; Hsu S
    Dermatol Online J; 2011 Aug; 17(8):14. PubMed ID: 21906494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.